Literature DB >> 27349985

The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

Michael F Emmons1, Fernanda Faião-Flores2, Keiran S M Smalley3.   

Abstract

Targeted therapy has proven to be beneficial at producing significant responses in patients with a wide variety of cancers. Despite initially impressive responses, most individuals ultimately fail these therapies and show signs of drug resistance. Very few patients are ever cured. Emerging evidence suggests that treatment of cancer cells with kinase inhibitors leads a minor population of cells to undergo a phenotypic switch to a more embryonic-like state. The adoption of this state, which is analogous to an epithelial-to-mesenchymal transition, is associated with drug resistance and increased tumor aggressiveness. In this commentary we will provide a comprehensive analysis of the mechanisms that underlie the embryonic reversion that occurs on targeted cancer therapy and will review potential novel therapeutic strategies designed to eradicate the escaping cells. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; EGFR; EMT; Lung cancer; Melanoma

Mesh:

Year:  2016        PMID: 27349985      PMCID: PMC5124530          DOI: 10.1016/j.bcp.2016.06.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  100 in total

Review 1.  Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.

Authors:  Stefan Grünert; Martin Jechlinger; Hartmut Beug
Journal:  Nat Rev Mol Cell Biol       Date:  2003-08       Impact factor: 94.444

Review 2.  An overview of epithelio-mesenchymal transformation.

Authors:  E D Hay
Journal:  Acta Anat (Basel)       Date:  1995

3.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

4.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.

Authors:  Suzanne Carreira; Jane Goodall; Laurence Denat; Mercedes Rodriguez; Paolo Nuciforo; Keith S Hoek; Alessandro Testori; Lionel Larue; Colin R Goding
Journal:  Genes Dev       Date:  2006-12-15       Impact factor: 11.361

Review 5.  Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.

Authors:  Takeshi Yoshida; Guolin Zhang; Eric B Haura
Journal:  Biochem Pharmacol       Date:  2010-05-24       Impact factor: 5.858

6.  NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway.

Authors:  Chun Sun; Lu Sun; Kai Jiang; Dong-Mei Gao; Xiao-Nan Kang; Cun Wang; Shu Zhang; Shan Huang; Xue Qin; Yan Li; Yin-Kun Liu
Journal:  Int J Biochem Cell Biol       Date:  2013-03-07       Impact factor: 5.085

7.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

8.  Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.

Authors:  F Vesuna; A Lisok; B Kimble; J Domek; Y Kato; P van der Groep; D Artemov; J Kowalski; H Carraway; P van Diest; V Raman
Journal:  Oncogene       Date:  2011-11-07       Impact factor: 9.867

9.  Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.

Authors:  Min Zheng; Ya-ping Jiang; Wei Chen; Kai-de Li; Xin Liu; Shi-yu Gao; Hao Feng; Sha-sha Wang; Jian Jiang; Xiang-rui Ma; Xiao Cen; Ya-jie Tang; Yu Chen; Yun-feng Lin; Ya-ling Tang; Xin-hua Liang
Journal:  Oncotarget       Date:  2015-03-30

10.  Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

Authors:  Helen Creedon; Laura Gómez-Cuadrado; Žygimantė Tarnauskaitė; Jozef Balla; Marta Canel; Kenneth G MacLeod; Bryan Serrels; Craig Fraser; Asier Unciti-Broceta; Natasha Tracey; Thierry Le Bihan; Teresa Klinowska; Andrew H Sims; Adam Byron; Valerie G Brunton
Journal:  Oncotarget       Date:  2016-03-08
View more
  20 in total

Review 1.  Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming.

Authors:  Custodia García-Jiménez; Colin R Goding
Journal:  Cell Metab       Date:  2018-12-20       Impact factor: 27.287

2.  Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.

Authors:  Guangming Chen; Chenxi Gao; Xuan Gao; Dennis Han Zhang; Shih-Fan Kuan; Timothy F Burns; Jing Hu
Journal:  Mol Cancer Ther       Date:  2017-11-22       Impact factor: 6.261

3.  Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Authors:  Daniel Verduzco; Brent M Kuenzi; Fumi Kinose; Vernon K Sondak; Zeynep Eroglu; Uwe Rix; Keiran S M Smalley
Journal:  Mol Cancer Ther       Date:  2017-11-13       Impact factor: 6.261

Review 4.  Proteomics advances for precision therapy in ovarian cancer.

Authors:  Marilyne Labrie; Nicholas D Kendsersky; Hongli Ma; Lydia Campbell; Jennifer Eng; Koei Chin; Gordon B Mills
Journal:  Expert Rev Proteomics       Date:  2019-09-13       Impact factor: 3.940

5.  HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Authors:  Michael F Emmons; Fernanda Faião-Flores; Ritin Sharma; Ram Thapa; Jane L Messina; Jurgen C Becker; Dirk Schadendorf; Edward Seto; Vernon K Sondak; John M Koomen; Yian A Chen; Eric K Lau; Lixin Wan; Jonathan D Licht; Keiran S M Smalley
Journal:  Cancer Res       Date:  2019-04-15       Impact factor: 12.701

6.  In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.

Authors:  Ileine M Sanchez; Timothy J Purwin; Inna Chervoneva; Dan A Erkes; Mai Q Nguyen; Michael A Davies; Katherine L Nathanson; Kristel Kemper; Daniel S Peeper; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2019-07-03       Impact factor: 6.261

Review 7.  Medulloblastoma: Molecular Classification-Based Personal Therapeutics.

Authors:  Tenley C Archer; Elizabeth L Mahoney; Scott L Pomeroy
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

8.  Shapeshifters in cancer: How some tumor cells change phenotype to evade therapy.

Authors:  Amanda B Keener
Journal:  Nat Med       Date:  2016-11-08       Impact factor: 53.440

9.  IL-6 and TNF-α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition.

Authors:  Guan-Sheng Shang; Lunxu Liu; Yi-Wei Qin
Journal:  Oncol Lett       Date:  2017-04-19       Impact factor: 2.967

10.  Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.

Authors:  Nicoletta Ferrari; Ilaria Granata; Matteo Capaia; Marina Piccirillo; Mario Rosario Guarracino; Roberta Venè; Antonella Brizzolara; Andrea Petretto; Elvira Inglese; Martina Morini; Simonetta Astigiano; Adriana Agnese Amaro; Francesco Boccardo; Cecilia Balbi; Paola Barboro
Journal:  Cell Commun Signal       Date:  2017-12-08       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.